Is Poseida Therapeutics, Inc. (PSTX) a Buy, Sell, or Hold?
Poseida Therapeutics, Inc.
NASDAQ:PSTX
$9.31 USD
-$0.02 (-0.21%)
- Volume
- 1.53M
- Average Volume
- 1.01M
- Market Capitalization
- $907.4M
- P/E Ratio
- -15.23
- Dividend Yield
- 0.00%
- Price Target
- $15.00
- Year High
- $9.42
- Year Low
- $1.87
- Payout Ratio
- $0.00
- Current Ratio
- $3.20
Industry, Sector & symbol
| Stock Exchange | NASDAQ Global Select |
| CEO | Dr. Kristin Yarema Ph.D. |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | PSTX |
| CUSIP | 73730P108 |
| CIK | 0001661460 |
| Web | https://www.poseida.com |
| Phone | 858 779 3100 |
| Currency | USD |
| Employees | 350 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.68 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.20 |
| Quick Ratio | 3.20 |
| Cash Ratio | 0.63 |
Sales & Book Value
| Annual Sales | $64.7M |
| Price / Sales | 6.01 |
| Cash Flow | -0.18 |
| Price / Cash Flow | -52.98 |
| Price / Book | 10.37 |
Price Target and Rating
| Average Stock Price Forecast | $15.00 |
| High Stock Price Forecast | $15.00 |
| Low Stock Price Forecast | $15.00 |
| Forecast Upside/Downside | -37.93% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 2 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.37 |
| Trailing P/E Ratio | -15.23 |
| PEG Ratio | -0.32 |
| P/E Growth | -0.32 |
| Net Income | $-123.43M |
| Net Margin | -39.37% |
| Pretax Margin | -40.25% |
| Return on Equity | -70.65% |
| Return on Assets | -20.23% |
Financials Score
| AltmanZ Score | 0.27 |
| Piotroski Score | 4.00 |
| Working Capital | 172.44M |
| Total Assets | 293.58M |
| Ebit | -51.64M |
| Market Cap | 907.4M |
| Total Liabilities | 206.37M |
Poll Results
About Poseida Therapeutics, Inc. (NASDAQ:PSTX) Stock
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogen ... eic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?
2024-11-28 10:56:22
From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pick, as it just reached a key level of support. PSTX's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
2024-11-27 18:14:00
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Poseida Therapeutics, Inc. (NasdaqGS: PSTX) to Roche Holdings, Inc. Under the terms of the proposed transaction, shareholders of Poseida will receive $9.00 in cash plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash (upon achieveme.
2024-11-27 11:00:48
The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?
2024-11-27 10:16:13
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
2024-11-26 20:50:00
NEW YORK , Nov. 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Poseida Therapeutics, Inc. (NASDAQ: PSTX ), relating to the proposed merger with Roche Holdings, Inc. Under the terms of the agreement, Poseida Therapeutics will be acquired at a price of $9.00 per share in cash at closing, plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $4.00 per share.
Frequently Asked Questions
-
What is the current Poseida Therapeutics, Inc. (PSTX) stock price?
-
Poseida Therapeutics, Inc.(NASDAQ:PSTX) stock price is $9.31 in the last trading session. During the trading session, PSTX stock reached the peak price of $9.42 while $1.87 was the lowest point it dropped to. The percentage change in PSTX stock occurred in the recent session was --0.21% while the dollar amount for the price change in PSTX stock was -$-0.02.
-
PSTX's industry and sector of operation?
-
The NASDAQ listed PSTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PSTX?
-
Dr. Kristin Yarema Ph.D. | President, Chief Executive Officer & Director
Mr. Harry J. Leonhardt Esq., J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary
Dr. Jeffrey W. Winkelman J.D., Ph.D. | Senior Vice President & Chief Patent Counsel
Mr. Mark J. Gergen J.D. | Executive Chairman of the Board
Mr. Loren Wagner | Chief Operations Officer -
How many employees does PSTX have?
-
Number of PSTX employees currently stands at 350. PSTX operates from 9390 Towne Centre Drive, San Diego, CA 92121, US.
-
Link for PSTX official website?
-
Official Website of PSTX is: https://www.poseida.com
-
How do I contact PSTX?
-
PSTX could be contacted at phone #858 779 3100 and can also be accessed through its website. PSTX operates from 9390 Towne Centre Drive, San Diego, CA 92121, US.
-
How many shares of PSTX are traded daily?
-
The average number of PSTX shares traded daily for last 3 months was 1.01M.
-
What is the market cap of PSTX currently?
-
The market value of PSTX currently stands at $907.4M with its latest stock price at $9.31